ITSN1 and systemic lupus erythematosus: Our findings indicates that the ITSN1-2/ceRNA axis may serve as a therapeutic target in NOD2/RIP2-driven diseases (e.g., cancer, RA, inflammatory bowel disease), but its inverse regulation in other disease like in SLE underscores the need for disease-specific biomarker panels.